Drug Approval | December 31, 2022
Zydus receives final approval from USFDA for Triazolam Tablets
Triazolam tablets are used on a short-term basis to treat insomnia (difficulty falling asleep or staying asleep)
Triazolam tablets are used on a short-term basis to treat insomnia (difficulty falling asleep or staying asleep)
Cipla and Ethris partner for the development of mRNA-based therapies
The new facility will be able to handle four times as many patients as the previous facility.
This ambitious anti-TB campaign, as part of IOCL’s CSR, aims to ensure early identification of presumptive TB and prompt diagnosis using high-sensitivity diagnostic tests at the doorstep
The current approval is first of the many fillings made by the company's CDMO partners from the flagship facility in Bangalore
The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze
Fulvestrant Injection, 250 mg/5 mL, has an estimated market size of US $71 million for twelve months ending Sep 2022 according to IQVIA
J. B. Chemicals & Pharmaceuticals has informed that the acquisition of the Razel franchise from Glenmark Pharmaceuticals Limited has been successfully completed.
Miravo to remain a Canadian controlled and operated company following closing of the transaction
Subscribe To Our Newsletter & Stay Updated
